AN2 Therapeutics Q1 net loss $10.0M; progresses oral epetraborole to Phase 2 for PV

AN2 Therapeutics, Inc.

2026-Q1 EPS reported -$0.29 vs consensus -$0.23 ▼ miss (-23.6%)

Net loss of $10.0M vs $10.6M in Q1 2025; R&D expenses $6.7M, down from $7.7M.
Cash and investments $85.3M as of Mar 31, 2026; raised $40M in March private placement; cash runway into 2029.
Oral epetraborole for polycythemia vera to enter Phase 2 in Q3 2026; data readouts expected from Q4 2026.
Phase 2 investigator-initiated trial for M. abscessus lung disease commenced in March 2026; topline results late 2027.
Chagas disease: Phase 1 trial completed dosing; Phase 1 and NHP efficacy data expected in Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.